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Abstract
Objective: To apply a scaled, preference-based measure to the evaluation of health-related quality of life (HRQoL)
in Parkinson’s disease (PD); to evaluate the relationship between disease-specific rating scales and estimated
HRQoL; and to identify predictors of diminished HRQoL.
Background: Scaled, preference-based measures of HRQoL ("utilities”) serve as indices of impact of disease, and
can be used to generate quality-adjusted estimates of survival for health-economic evaluations. Evaluation of
utilities for PD and their correlation with standard rating scales have been limited.
Methods: Utilities were generated using the Health Utilities Index Mark III (HUI-III) on consecutive patients
attending a PD Clinic between October 2003 and June 2006. Disease severity, medical, surgical (subthalamic
nucleus deep brain stimulation (STN-DBS)), and demographic information were used as model covariates.
Predictors of HUI-III utility scores were evaluated using the Wilxocon rank-sum test and linear regression models.
Results: 68 men with a diagnosis of PD and a mean age of 74.0 (SD 7.4) were included in the data analysis. Mean
HUI-III utility at first visit was 0.45 (SD 0.33). In multivariable models, UPDRS-II score (r
2 = 0.56, P < 0.001) was highly
predictive of HRQoL. UPDRS-III was a weaker, but still significant, predictor of utility scores, even after adjustment
for UPDRS-II (P = 0.01).
Conclusions: Poor self-care in PD reflected by worsening UPDRS-II scores is strongly correlated with low generic
HRQoL. HUI-III-based health utilities display convergent validity with the UPDRS-II. These findings highlight the
importance of measures of independence as determinants of HRQoL in PD, and will facilitate the utilization of
existing UPDRS data into economic analyses of PD therapies.
Introduction
Parkinson’s disease (PD) is a chronic neurodegenerative
illness that results from progressive cell death affecting
movement, mood, cognition and autonomic function
[1]. The prevalence of PD is approximately 1% among
those aged greater than 65 [2]. A 2005 estimate placed
the number of individuals aged over 50 living with PD
in the world’s ten most populous countries at 4.1-
4.6 million, with projected increases to 8.7-9.3 million
by 2030 [3].
The precise effect of optimal PD treatment on life
expectancy is unclear, but living with this chronic
degenerative illness is thought to have a profound nega-
tive impact on health-related quality of life (HRQoL)
due to both disease manifestations, and the adverse
effects of medical and surgical management strategies
[4-9]. As such, the public health burden of PD is signifi-
cant and increasing, and ways of assessing the impact of
therapeutic interventions on HRQoL are needed for
optimal patient care and for allocation of scarce health-
care resources [10].
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consists of assessments in 4 domains including, mood
and cognition (UPDRS I), activities of daily living
(UPDRS II), motor symptom severity (UPDRS III) and
complications of treatment (UPDRS IV) [11]; it is the
standard and most commonly used rating scale for
disease severity in PD, however, it does not explicitly
capture HRQoL, and has not been validated for this
purpose. Generic measures of HRQoL take into account
such dimensions as functional capacity, emotional well
being, and role function that may not be adequately
captured by disease rating scales [12]. Furthermore, gen-
eric HRQoL instruments allow comparison of health-
related quality of life across different disease states.
While questionnaires for evaluation of HRQoL in PD
(such as the PD-39 and Parkinson’s Disease Quality of
Life instruments [13] have been developed, these instru-
ments are neither scaled nor preference-based. Scaled,
preference-based HRQoL measures (“health utilities”)
can also be used to “quality-adjust” survival estimates,
and are easily incorporated into health economic analy-
sis of medical interventions [14].
Given the increasing awareness of HRQoL as an
important end-point that may not correlate directly with
physical disability, there has been a growing literature
documenting the predictors of low HRQoL in PD
[15-17]. However, there have been relatively few
attempts to quantify health utilities [9], or to evaluate
the relationship between utilities and PD-specific rating
scales such as the UPDRS. As there is a large volume of
intervention-specific data already accumulated using the
standard UPDRS, and very limited amount of data cap-
tured regarding HRQoL, a means of translating UPDRS
data into HRQoL would be extremely valuable and
would permit cost-utility analysis of interventions incor-
porating data that have already been collected. We
sought to measure both disease severity and health utili-
ties in PD, through parallel application of disease speci-
fic rating scales and the Health Utilities Index-III (HUI-
III), an easy to use, well-validated instrument useful for
approximation of scaled, preference-based health utility
measures of HRQoL. Our objectives were to evaluate
the relationship between disease severity (as measured
by standard rating scales), and estimated health-related
quality of life in individuals with PD, and to identify
predictors of diminished HRQoL.
Methods
Subjects
The study population consisted of individuals attending
the Philadelphia Veterans Administration Parkinson’s
Disease Research, Education and Clinical Center
(PADRECC) between October 2003 and June 2006 with
an ICD-9 diagnosis of Parkinsonism or PD. The
PADRECC is a multidisciplinary center providing sub-
specialty care to veterans with PD and other movement
disorders and serves a catchments area that covers
Pennsylvania, New England and the Mid-Atlantic States.
The population of veterans receiving medical care
through the Veterans Administration healthcare system
in this area is 998,061, of whom approximately 5303
have diagnosed PD. Individ u a l sf r o mt h i sc o h o r ta r e
referred to PADRECC for expert guidance on disease
management. Charts of all patients attending the
PADRECC during the study period were reviewed. As
this was a longitudinal prospective cohort study with
respect to the outcome of interest (HUI-III), only indivi-
duals with at least 2 completed HUI-III questionnaires
(from 2 separate visits) were eligible for inclusion.
Review of the diagnosis of parkinsonism was further
scrutinized and only individuals fulfilling United King-
dom Brain Bank Criteria [18] for idiopathic PD (IPD)
were included in the database. Information abstracted
from the medical record included age of disease onset,
disease duration, gender, marital status, living arrange-
ments, and level of education, as well as information on
co-morbid medical conditions that might reduce health-
related quality of life [19], including diabetes mellitus
[20], coronary artery disease [21], stroke [22] and arthri-
tis [23]. PD severity was assessed using UPDRS ADL
and motor sub-scores (UPDRS II and III) [11], the
Hoehn and Yahr Score (H+Y) [24], and the Schwab and
England Disability Score (S+E) [25]. Assessments were
performed in the “on” state. Medication dosages, pre-
sence of motor fluctuations and dyskinesia, surgical
intervention (STN-DBS), and non-motor symptoms
including depression, dementia, psychosis, drooling,
urinary dysfunction and constipation were also
abstracted from the records. Depression, dementia and
psychosis were deemed to be present if explicitly docu-
mented in the chart. Additionally, these diagnoses were
presumed if anti-depressants, neuroleptics, cholinester-
ase inhibitors, or other cognitive enhancing drugs were
prescribed. The study was approved by the Institutional
Review Board of the Philadelphia VA Hospital. All ana-
lyses were performed using Intercooled Stata Version
10.0 (Stata Corporation, College Station, TX).
Measurement of HRQoL
Health utilities are scaled, preference-based generic
measures of health-related quality of life that lie on a
zero-to-one scale, with a utility of 1 equivalent to per-
fect health, and 0, equivalent to death. (Scores less than
0 are possible, and could be interpreted as health states
less desirable than death). While utilities can be elicited
using “standard-gamble” or “time-tradeoff” methods,
these are intellectually rigorous, and may be upsetting
to study subjects [14]. The use of a “health index”
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tion of health utilities, including ease of administration,
avoidance of distressing scenarios, and the potential for
self-administration by subjects [26]. The HUI-III is an
easy to use, well-validated instrument useful for approxi-
mation of scaled, preference-based health utility mea-
sures of HRQoL. In the HUI-III, rankings on eight
health domains (including cognition, vision, hearing,
speech, ambulation, dexterity, emotion, and pain) are
transformed using a function that maps these domains
onto utility scores that reflect community preferences
[27]. HUI-III data were obtained from medical records,
as the instrument was incorporated into the standard
clinic intake form in October 2003.
Statistical Analyses
We performed both cross-sectional analyses on baseline
data collected for the study cohort, and longitudinal
analyses in which we evaluated change in utility scores
over time. Baseline HUI-III-based utility scores were
evaluated for the cohort as a whole using descriptive
statistics. The relationships between UPDRS scores and
raw and log-transformed HUI-III utilities were assessed
graphically. We evaluated the association between base-
line patient characteristics (including PD severity) and
baseline HUI-III scores through construction of bi-vari-
able least-squares regression models, with standard
errors adjusted to account for multiple measurements
on some study subjects. Characteristics that were asso-
ciated with HUI-III scores at the P < 0.15 level were
considered candidate covariates in multivariable regres-
sion models. Multivariable models were constructed
using a stepwise selection algorithm, with covariates
retained for P < 0.15 [28]. We created a multivariable
model (“Model 1”)i nw h i c ht h eU P D R SI Ia n dI I Is u b -
scores were used as candidate covariates, but also cre-
ated an alternate model in which components of
UPDRS II and III, rather than overall scores, were
included individually as covariates. The balance between
model precision and parsimoniousness was assessed
using Akaike’s information criterion (AIC) [29]. Interac-
tion between model covariates was explored using mul-
tiplicative interaction terms.
Longitudinal changes over time in HUI-III scores, and
UPDRS scores, were evaluated using repeated-measures
ANOVA. For the subset of individuals (N = 20) for
whom repeated HUI-III and UPDRS scores were avail-
able, we further explored the relationship between
change in HUI-III scores and UPRDS III scores using
the approach of Fitzpatrick et al. [4], with calculation of
changes between first and last measurements for both
scores, and rescaling of scores by dividing by standard
deviations in scores. Correlation between changes were
evaluated through calculation of Spearman correlation
coefficients. We also created multivariable regression
models to evaluate predictors of change in HUI-III-
based utilities between first and last evaluation.
Results
Study Population
We screened 156 consecutive patients assessed for par-
kinsonism in our clinic over the study period. Of these
88 (57%) had more than 1 evaluation of health-related
quality of life, and so were included in the study. Of
these individuals, 20 had parkinsonism but did not meet
Brain Bank criteria for PD; among excluded individuals
six were diagnosed with likely vascular parkinsonism;
eight were excluded based on atypical features not sug-
gestive of idiopathic Parkinson’s disease, two each were
excluded based on diagnoses of multisystem atrophy
and suspected diffuse Lewy body dementia, and one
each was excluded based on diagnoses of fronto-tem-
poral dementia, and progressive supranuclear palsy.
Baseline patient characteristics are outlined in Addi-
tional File 1: Table S1. All 68 included individuals were
male. Of these, all had at least 2 visits, 28 had 3 visits
and 3 had 4 visits during the study period. Median fol-
low-up time was 210 days (interquartile range 159-546).
The mean age at first evaluation was 73.6 years. The
majority of patients lived at home either independently
or with family assistance. Most patients had at least a
high school education; 18% achieved grade school or
less.
Comorbid medical conditions identified in the cohort
included coronary artery disease, stroke, arthritis and
diabetes mellitus. On average subjects had disease dura-
tion of 8 years at the time of the first recorded visit,
with moderate disease severity (reflected by an average
UPDRS III score of 30 and H+Y score of 2.8). Mean
dosage of anti-parkinsonian medications, expressed as
levodopa equivalent dose (LED) [30], was 719 mg/day.
Motor fluctuations and dyskinesia were relatively
uncommon; there was a high prevalence of non-motor
symptoms of depression, urinary frequency and urgency,
and constipation. Cognitive impairment was present in
approximately 15% of patients at first visit; the mean
baseline mini-mental status exam score in the cohort
was 27.5 (SD = 3.0).
Baseline Health-Related Quality of Life
T h ea v e r a g ev a l u ef o rb a s e l i n eH U I - d e r i v e du t i l i t y
weights was 0.42 (range -0.15 to 1.0). In univariable
regression models, stroke was significantly associated
with reduced HUI-derived utility weights; borderline sig-
nificant associations were seen with diabetes and marital
status (Additional file 1; Table S1). However, several dis-
ease characteristics were found to be predictive of low
baseline HRQoL, including disease duration, disease
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UPDRS II and III scores (Figure 1). Consistent with this,
collinear variables such as individual UPDRS motor sub-
scores of bradykinesia, rigidity, and summed axial sub-
scores (PIGD and ADL-axial) also predicted lower utility
scores.
Motor fluctuations, though mild in the few patients
that endorsed them, were correlated with low baseline
quality of life. Non-motor symptoms of dementia,
depression, psychosis, urinary dysfunction, and drooling
were all significantly associated with decreased HRQoL
in univariable analysis.
Multivariable Regression
We created two best-fit multivariable regression models
for prediction of HUI-III utilities based on UPDRS
scores, sub-scores, and other patient characteristics
(Table 1). The first model (“Model 1”)u s e dU P D R S - I I
and -III scores as candidate covariates, while “Model 2”
used UPDRS sub-scores (tremor, bradykinesia, rigidity,
PIGD, ADL-axial) as candidate covariates. In Model 1,
both UPDRS-II scores and S+E scores were independent
predictors of HRQoL; UPDRS-III was no longer signifi-
cantly associated with HRQoL after controlling for
UPDRS-II and S+E scores.
In Model 2, UPDRS axial sub-scores (PIGD and ADL-
axial) and S+E scores were independent predictors of
HRQoL; increased disease duration was associated with
increased HRQoL after adjustment for axial sub-scores
and S+E scores. Both models explained a high propor-
tion of between-subject variation in HRQoL, and both
models displayed excellent predictive ability (Figure 2).
Figure 1 Relationship between UPDRS II scores (X-axis) and HUI-III utlity estimates (Y-axis) showing approximately linear realtionship.
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The average time interval between first and last assess-
ment in the cohort was 6.6 months (SD 4.9). The mean
reduction in HUI-III utilities between first and last
assessment was 0.014 (SD 0.25); 34 individuals (50%)
experienced a net reduction in utility, 33 (49%) experi-
enced a gain in utility, and 1 (1%) had no change in
health utility. When utilities were analyzed using
repeated measures ANOVA, there was no reduction in
utility scores with succeeding visits (P = 0.67).
Significant changes were identified in Schwab and
England scores (P = 0.02), but not in UPDRS-III scores
(P = 0.66) or Hoehn and Yahr scores (0.11) using a
similar approach. Repeated measurements of UPDRS-II
scores were obtained in only 20 of 68 subjects; there
was no significant change over time in these scores
(0.50).
Notwithstanding the small number of individuals with
both repeated HUI-III and UPDRS measurements, sig-
nificant Spearman correlations were identified between
Table 1 Best Fit Multivariable Regression Models with UPDRS Summary Scores as Candidate Variables (Model 1) and
UPDRS Component Sub-Scores as Candidate Variables (Model 2)
Multivariable Model 1
r
2 = 0.69, AIC = -21.4
Multivariable Model 2
R
2 = 0.76, AIC = -33.1
Predictor Coefficient 95% CI P-value Coefficient 95% CI P-value
Intercept 0.25 —— 0.17 — —
UPDRS II -.015 -0.024 to -0.005 0.003 —— —
Axial Subscore —— — -0.030 -0.043 to -0.018 <0.001
Schwab and England Score 0.006 0.002 to 0.010 0.003 0.005 0.003 to 0.008 <0.001
Pharmacotherapy for Dementia -0.21 -0.37 to -0.04 0.02 —— —
Duration of disease —— — 0.016 0.004 to 0.027 0.007
Figure 2 Relationship between measured HUI-III utility estimates (X-axis) and predicted estimates (Y-axis) using multivariable model 1
(red circles) and multivariable model 2 (green circles) which are described in greater detail in the text. For both models, the relationship
between observed and expected utility estimates was approximately linear.
Kleiner-Fisman et al. Health and Quality of Life Outcomes 2010, 8:91
http://www.hqlo.com/content/8/1/91
Page 5 of 9changes in HUI-III scores (rescaled by dividing by stan-
dard deviations in changes) and rescaled change in
UPDRS-III scores (rho = 0.25, P = 0.045), Schwab and
England scores (rho = -0.38, P = 0.003), and Hoehn and
Yahr scores (rho = 0.31, P = 0.017). The largest correla-
tion coefficient was observed for rescaled change in
UPDRS-II scores, though because of the small numbers
of individuals with repeated UPDRS-II measurement
this was not statistically significant (rho = 0.39, P =
0.093). In a multivariable regression model, changes in
HUI-III utilities were predicted only by changes in
UPDRS-III scores (change per unit increase in UPDRS-
III score -0.009, 95% CI -0.016 to -0.002) and time
between first and last evaluation (change per week
-0.017, 95% CI -0.028 to -0.006).
Discussion
Although Parkinson’s disease is most prominently iden-
tified with physical symptoms such as tremors and aki-
nesia, this disease has a substantial impact beyond
motor impairment and physical disability with an on
overall reduction in all health-related quality of life
dimensions including social and emotional well-being.
To date, the relatively limited application of existing
tools for the measurement of health-related quality of
life (HRQoL) has made it difficult to compare the loss
of HRQoL in PD to that experienced by individuals with
other chronic conditions [9]. Using a health utilities
“index” approach we found a substantial reduction in
HRQoL in a cohort of individuals attending a PD speci-
alty clinic, similar to other reports [16,31-34]. However,
we also found that diminished HRQoL as measured by
changes in health utilities was closely correlated with
changes in scores on a PD-specific disease severity mea-
sure, the UPDRS.
HUI and UPDRS
We are aware of at least one other prior effort to map
health utilities onto UPDRS scores [9]; Siderowf and
colleagues identified agreement between overall UPDRS
scores and the HUI-II, as well as other utility-based
instruments. Our mean utility estimate (0.42) is lower
than that reported by Siderowf et al. (with a mean utility
of 0.74), and this may reflect the fact that our cohort
was assembled at a clinic to which patients were
referred due to complexities of medical management,
and could also reflect a different profile of co-morbid
conditions in the two populations. It may also, in part,
reflect the fact that HUI-III includes domains (such as
vision and hearing) that are not included in HUI-II, and
which may be sources of diminished global quality of
life in the age group at greatest risk of PD.
In comparison to the Siderowf study, our study
further refined the relationship between health utilities
and UPDRS scores. Perhaps surprisingly, we found that
these reductions were most strongly correlated with the
self-care component of the UPDRS (UPDRS-II), rather
than the UPDRS-III motor sub-score. This finding
serves as an important reminder that loss of indepen-
dence may be an important source of morbidity in indi-
viduals with PD. As we demonstrated in regression
analyses (Figure 1), the correlation between UPDRS-II
and HUI scores was so substantial that it may be possi-
ble to generate approaches whereby existing disease-spe-
cific scores can be transformed into health utility
estimates, for the purposes of comparing the health bur-
d e na s s o c i a t e dw i t hP Dt ot h a ts e e ni no t h e rc h r o n i c
medical conditions, and in order to utilize HRQoL as
the outcome of interest in economic evaluations of
novel therapies for PD.
Predictors of Low Baseline HRQoL
Other important predictors of low baseline HRQoL in
this study included reductions in S+E disability scores,
and higher axial sub-scores (PIGD). Though health-
related quality of life and self-care ability in PD are
inextricably linked to severity of motor dysfunction, the
relationship between motor impairment and reduction
in health-related qualityo fl i f em a yb ec o m p l e xa n d
indirect, as demonstrated by our failure to find an inde-
pendent relationship between UPDRS motor III sub-
scores and HUI, after controlling for UPDRS-II and
other scores. These results are consistent with previous
findings that motor impairment in and of itself does not
reduce health-related quality of life but the functional
consequences of poor motor function including loss of
self-care capabilities, inability to ambulate and loss of
independence and its emotional consequences that may
provide the link between physical impairment and low
HRQoL [16,35].
We failed to find an association between either cogni-
tive impairment or evidence of depression and low
HRQoL, similar to one other study [15]. However this
lack of association may reflect the fact that our study
population was relatively intact cognitively (mean
MMSE = 27.5/30). Nonetheless, it is also well-recog-
nized that the MMSE is insensitive to capturing early
cognitive decline in PD patients [36] and therefore we
may not have identified individuals with subtle cognitive
changes. Alternatively, it is possible that the mild cogni-
tive changes in this cohort were insufficient to contri-
bute substantially to low HRQoL.
Six prior longitudinal studies have evaluated HRQoL
in PD. The first, based on a community-based cohort,
found no relationship between any baseline clinical
characteristics and reduction in HRQoL [37]. Another
study [31] using both disease specific measures (PDQL
and PDQ-39) and a generic utilities-based instrument
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using the EQ-5 D. However, low disease-specific quality
of life scores in general were predicted by depression,
motor complications, cognitive impairment, and gait
instability. The lack of change in the EQ-5 D was attrib-
uted to short follow-up time (12 months); the authors
also postulated that the EQ-5 D was not sufficiently sen-
sitive to pick up the subtle changes that may have
occurred over only 1 year. A third study, by Fitzpatrick
and colleagues [4], identified correlation between a gen-
eric HRQoL measure (SF-36) and a disease-specific
HRQoL measure (the PDQ-39) (neither of them scaled
nor preference-based) and also identified correlation
between these measures in change over time [4], similar
to the findings reported here.
Forsaa et al. [15] prospectively followed patients for 4
to 8 years, with HRQoL measured using the Nottingham
Health Profile (NHP), a validated generic instrument.
This study found that the greatest predictor of reduction
in HRQoL was decline in physical mobility (as captured
in part by worse S+E scores and higher H+Y scores),
though depression and sleep disturbance were also
important contributing factors; Contrary to our findings,
UPDRS-II sub-score was not found to predict reduction
in HRQoL.
Marras et al. also evaluated predictors of diminished
HRQoL [16] using a large cohort from the DATATOP
database. HRQoL was evaluated using the physical com-
ponent sub-score (PCS) and mental component sub-
score (MCS) of the SF-36, a generic HRQoL scale.
Depression and self-rated cognitive function predicted
low PCS; low MCS was predicted by older age and S+E
disability scores at baseline. HRQoL and PIGD sub-
scores declined in parallel over time. As in our study,
these authors suggested that physical impairments asso-
ciated with PD did not directly reduce health-related
quality of life. Rather, lower health-related quality of life
reflected diminished ability to perform ADLs, with
increased dependence on others. Most recently, Brown
and colleagues evaluated the relative performance of SF-
36 and PD-specific quality of life instruments in predict-
ing change in criterion indices of disease severity and
quality of life (measured with a visual analogue scale);
disease-specific measures outperformed generic mea-
sures in explaining variance in criterion indices, though
SF-36 was more responsive to change over time [13].
Change Over Time
Health utility estimates and most indices of PD severity
were relatively stable over the course of our study,
which may reflect the relatively short duration of study,
and perhaps also the fact that notwithstanding the
decline in status expected with a degenerative disease
like PD, at least some subjects may have experienced
improved health-related quality of life as a result of opti-
mized medical management following referral to the
PADRECC. Changes in utility were correlated with
changes in multiple PD-specific measures, though our
ability to document relationships between changes in
health-related quality of life and changes in UPDRS-II
scores were limited by the fact that repeated UPDRS-II
scores were available in only a small subset of subjects.
Limitations
This study had several important limitations. Our failure
to identify a link between depression and low HRQoL
contrasts with the results of other studies [15,38-45] and
could reflect misclassification of depression, which was
based on records of physician diagnosis or prescription
of antidepressant medication, rather than through stan-
dardized prospective assessment. Studies that have iden-
tified associations between depression and low HRQoL
have generally confirmed depression using validated
mood assessment instruments. As such, our failure to
find an association between depression and HRQoL in
patients with PD should be interpreted with caution.
Other limitations of this study relate to the generaliz-
ability of findings in a cohort of male U.S. veterans: our
findings may not be generalizable to non-veterans or to
women, as they were not represented in our cohort. Pre-
vious epidemiological surveys have suggested gender dif-
ferences in PD; Men have been described to have earlier
symptom onset [46], increased incidence of cognitive
impairment [47], increased risk of pathological gambling
[48] and decreased rates of depression [49]. Women
have cited greater disability and lower health-related
q u a l i t yo fl i f ei nc o m p a r i s o nt om e nw i t hP D[ 5 0 ] .
Finally, as discussed above, we had a limited ability to
assess changes in UPDRS-II scores over time as these
measurements were repeated infrequently.
Conclusions
In conclusion, we sought to evaluate health-related qual-
ity of life in PD using a “health utilities index” approach,
and to assess the relationship between health utility
scores and PD severity as measured using standard dis-
ease-specific tools. In cross-sectional analyses, we identi-
fied ADL-related components of the UPDRS as most
closely linked to health-related quality of life, a finding
that underscores the fact that PD manifests in dimen-
sions aside from movement and motor control. Our
findings, although preliminary, may pave the way for
translation of PD-specific measures of disease severity
into health utility scores, particularly if our findings can
be replicated and externally validated in other popula-
tions and by other investigators.
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